Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + Nivolumab + Ipilimumab in Recurrent Gynecologic Carcinosarcoma
NCT04149275Phase 2Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in Gynecologic carcinosarcoma (GCS), sponsored by University of Alabama at Birmingham. Planned start Feb 2021; status: withdrawn.
02
Drugs
cabozantinib
03
Conditions
Gynecologic carcinosarcoma (GCS)
Beyond the preview
Go deeper on NCT04149275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149275.